Drugs Begining With“p”
Investigated for use/treatment in candidiasis, fungal infections, and saliva and salivary gland dysfunction.
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
For the potential treatment of panic and anxiety disorders.
Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
For treatment of oral mucositis associated with chemotherapy and radiation therapy.
For the treatment of schizophrenia.
For prophylaxis of respiratory diseases casued by respiratory syncytial virus.
A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids. [PubChem]
Not Available
Not Available
For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.
For the treatment of moderate or severe hypercalcemia associated with malignancy
For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa™), chronic pancreatitis (Viokace™ in combination with a proton pump inhibitor), and pancreatectomy (Viokace™ in combination with a proton pump inhibitor).
Used as a muscle relaxant during anesthesia and surgical procedures.
For the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.